Table 1.

Baseline Characteristics.

	Total (n = 24)
Age, years
Mean (SD)	57.3 (13.2)
Median [range]	57.6 [30.4–75.1]
IQR	48.0–69.3
ECOG, n (%)
0	9 (38 %)
1	10 (42 %)
2	5 (21 %)
Time from initial diagnosis of BC to registration, years
Mean (SD)	3.4 (2.5)
Median [range]	3.2 [0.1–10.2]
IQR	1.5–4.8
Prior systemic therapy, n (%)
HER2-targeted therapy	24 (100 %)
Chemotherapy	22 (92 %)
Hormone therapy	9 (38 %)
Number of brain lesions, n (%)
1	11 (46 %)
2	5 (21 %)
3	5 (21 %)
4	1 (4 %)
5	2 (8 %)
Extra cranial disease (ECD) status, n (%)
Absent	7 (29 %)
Controlled on HER2-targeted therapy	11 (46 %)
Treatable with HER2-targeted therapy	6 (25 %)
Extracranial disease sites
Bone	13 (54 %)
Liver	11 (46 %)
Lung	8 (33 %)
Lymph Node	6 (25 %)
Other	4 (17 %)